BCAX Stock Analysis: Bicara Therapeutics Common | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 1.920m USD | 12M Return: 237.4% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 18.8M
Warnings
No concerns identified
Tailwinds
Seasonality 1.8 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Bicara Therapeutics Inc. (NASDAQ: BCAX) is a clinical-stage biopharmaceutical company developing bifunctional therapies for solid tumors. Its lead candidate, ficerafusp alfa, is a bifunctional antibody that pairs an EGFR-directed monoclonal antibody with human transforming growth factor beta (TGF-β), designed to address tumors through a dual mechanism. Because the company is clinical-stage, it has no approved products on the market and its value is primarily tied to the progression of its pipeline and the capital needed to fund ongoing trials.
Founded in 2018 and headquartered in Boston, Massachusetts, Bicara operates within the biotechnology sub-industry of the health care sector. The company went public on September 13, 2024, and currently has a small-cap market valuation of approximately $1.4 billion USD. Its Boston base places it in one of the United States major biopharma clusters, where it can access research talent, academic medical centers, and a deep network of oncology-focused investors and partners.
- Ficerafusp alfa Phase 2 trial data readout in HNSCC
- FDA fast track designation progresses for lead oncology candidate
- Cash runway extension through pivotal trial milestones remains key focus
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.21 > 0.02 and ΔFCF/TA -2.58 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.21 > 3% & CFO -116.2m > Net Income -157.3m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 13.85 > 1.5 & < 3 |
| Outstanding Shares: last quarter (60.7m) vs 12m ago 11.50% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.0%; Δ 0.0% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.91 (Total Current Assets 544.9m - Total Current Liabilities 39.3m) / Total Assets 553.6m |
| B: -0.75 (Retained Earnings -415.2m / Total Assets 553.6m) |
| C: -0.30 (EBIT TTM -157.1m / Avg Total Assets 515.8m) |
| D: 12.97 (Book Value of Equity 514.0m / Total Liabilities 39.6m) |
| Altman-Z'' = 15.11 = AAA |
As of July 08, 2026, the stock is trading at USD 30.40 with a total of 1,840,080 shares traded. Over the past week, the price has changed by +3.61%, over one month by +51.24%, over three months by +42.79% and over the past year by +237.40%.
Current recommended Stop Loss: 28.50 (which is 6.2% or 1.4 ATR below the current price).
Bicara Therapeutics Common has received a consensus analysts rating of 4.43. Therefore, it is recommended to buy BCAX.
- StrongBuy: 4
- Buy: 2
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 31.5 | 3.5% |
P/B = 3.7061
Revenue TTM = 0.0 USD
EBIT TTM = -157.1m USD
EBITDA TTM = -157.0m USD
Long Term Debt = 301k USD (estimated: total debt 1.44m - short term 1.14m)
Short Term Debt = 1.14m USD (from shortTermDebt, last quarter)
Debt = 1.44m USD (from shortLongTermDebtTotal, last quarter) (leases 1.44m already included)
Net Debt = -538.3m USD (calculated: Debt 1.44m - CCE 539.8m)
Enterprise Value = 1.38b USD (1.92b + Debt 1.44m - CCE 539.8m)
Interest Coverage Ratio = unknown (Ebit TTM -157.1m / Interest Expense TTM 0.0)
EV/FCF = -11.85x (Enterprise Value 1.38b / FCF TTM -116.6m)
FCF Yield = -8.44% (FCF TTM -116.6m / Enterprise Value 1.38b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = 2.50 (Enterprise Value 1.38b / Total Assets 553.6m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 1.44m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -124.1m (EBIT -157.1m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 13.85 (Total Current Assets 544.9m / Total Current Liabilities 39.3m)
Debt / Equity = 0.00 (Debt 1.44m / totalStockholderEquity, last quarter 514.0m)
Debt / EBITDA = 3.43 (negative EBITDA) (Net Debt -538.3m / EBITDA -157.0m)
Debt / FCF = 4.62 (negative FCF - burning cash) (Net Debt -538.3m / FCF TTM -116.6m)
Total Stockholder Equity = 438.3m (last 4 quarters mean from totalStockholderEquity)
RoA = -30.50% (Net Income -157.3m / Total Assets 553.6m)
RoE = -35.89% (Net Income TTM -157.3m / Total Stockholder Equity 438.3m)
RoCE = -35.82% (EBIT -157.1m / Capital Employed (Equity 438.3m + L.T.Debt 301k))
RoIC = -24.08% (negative operating profit) (NOPAT -124.1m / Invested Capital 515.4m)
WACC = 12.08% (E(1.92b)/V(1.92b) * Re(12.09%) + D(1.44m)/V(1.92b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 12.09% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 98.88 | Cagr: 6.15%
[DCF] Fair Price = unknown (Cash Flow -116.6m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.71 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: N/A | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.83 | Chg30d=N/A | Revisions=-55% | Analysts=13
EPS next Quarter (2026-09-30): EPS=-0.85 | Chg30d=N/A | Revisions=-55% | Analysts=13
EPS current Year (2026-12-31): EPS=-3.48 | Chg30d=N/A | Revisions=-79% | GrowthEPS=-38.0% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-3.63 | Chg30d=N/A | Revisions=-70% | GrowthEPS=-4.5% | GrowthRev=+0.0%
[Analyst] Revisions Ratio: -81% (up=2, down=32)